NAMS

NewAmsterdam Pharma Company N.V. (NAMS) | Rumor.io

NewAmsterdam Pharma

NAMS

Attention (50-day avg)0%

Attention rank (50-day avg)#1,081

Bullish sentiment (50-day avg)37%

Price to earnings ratio-13.2

Market capitalization2.8B

Earnings per share-2.26

Dividend yield (TTM)2.8%

Revenue (annual)22.5M

Net income (annual)-203.8M

Social

What share of all stock conversation is about NAMS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% +0	0% 0

Sep 4

NewAmsterdam Pharma Company N.V.'s ($NAMS) PREVAIL trial is expected to show the efficacy of obicetrapib in reducing cardiovascular events through LDL-C/apoB lowering, a separate and well-established biological pathway.
The recent HORIZON trial result, which showed that a substantial Lp(a) reduction did not significantly reduce cardiovascular events, may weaken the argument that obicetrapib's Lp(a) reduction should be expected to produce a large additional benefit.
The PREVAIL trial is crucial in determining the effectiveness of obicetrapib, and its success despite the HORIZON failure would suggest that lowering LDL/ApoB remains the major driver of its cardiovascular benefit.

Generated by AI

Sentiment

Of the messages about NAMS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100% +25	14.83% -69.47	71.65% +0.3
Bearish	0% 0	0% -25	85.17% +69.47	28.35% -0.3

Dec 10

$NAMS has shown promising results in its cholesterol drug, with a 21% reduction in major cardiovascular events over a year.
Obicetrapib, NewAmsterdam's drug, has the potential to outperform statins in total sales and has no real competition, making it a valuable asset in the market.
The company's stock has surged after positive trial results, with analysts expecting a significant increase in valuation, potentially reaching $5 billion.

Generated by AI

Topics

Of the messages about NAMS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	93.65%	72.56%
Technical Analysis	0%	0%	3.17%	10.86%
Analysts	0%	0%	0%	7.17%
Controversies	0%	0%	1.59%	0.22%
Macro	0%	0%	1.59%	6.05%
Earnings	0%	0%	0%	3.14%

Dec 10

NewAmsterdam Pharma announces positive topline data from pivotal Phase 3 BROADWAY clinical trial evaluating obicetrapib in patients with atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia.
NewAmsterdam Pharma commences $300 million public offering of ordinary shares and pre-funded warrants.
Obicetrapib clinches third positive trial, with shares surging in response to the news.

Generated by AI

Community

Of the messages about NAMS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	19.23%	46.15%	51.42%	44.19%
Newcomers	80.77%	53.85%	48.58%	55.81%

Jun 9

The NewAmsterdam Pharma Company N.V. ($NAMS) has announced positive topline results from its Phase 3 BROADWAY clinical trial for Alzheimer's Disease, showing significant reductions in biomarkers linked to the disease.
The trial's results suggest that the company's cholesterol drug, obicetrapib, may also have a preventive effect on Alzheimer's, with a potential sales range of $15-20 billion if the pills are priced at $3 per piece.
The company's stock has rallied on the positive news, with a 6.11% gap up and a 6.74% intraday gain, and institutional interest is growing, with 168 funds showing a 16.7% increase in holdings.

Generated by AI

- SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms- - The study will evaluate changes in blood-based biomarkers associated with Alzheimer’s disease, including p-tau 217, and additional cognitive and functional measures- NAARDEN, the Netherlands and MIAMI, Sept. 29, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a lat

1d agoYahoo! Finance Canada

NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has cleared a major regulatory hurdle. On September 21, it announced European Commission approval of Ubeslo, containing 10 mg of obicetrapib, and Evlarco, combining 10 mg of obicetrapib with 10 mg of ezetimibe. These are the products’ first global approvals. The medicines lower low-density lipoprotein cholesterol, or LDL-C, commonly called […]

7d agoYahoo Finance

Also Discussed

Investors talking about NAMS also mention

#	Name	Attention
1	Esperion Therapeutics Inc.ESPR	0%new
2	Mineralys Therapeutics, Inc.MLYS	0%+0
3	Apogee Therapeutics, Inc. - Common StockAPGE	0%0
4	Kyverna Therapeutics, Inc.KYTX	0%0
5	Crinetics Pharmaceuticals IncCRNX	0%new
6	Structure Therapeutics Inc. American Depositary SharesGPCR	0%new
7	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02
8	Taysha Gene Therapies, Inc.TSHA	0%0
9	Biohaven Ltd.BHVN	0%-0.01
10	Ionis Pharmaceuticals, Inc.IONS	0%new

NewAmsterdam Pharma Company N.V.

Healthcare
Biotechnology

NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company focused on developing oral therapies for cardiometabolic diseases, especially patients whose current lipid-lowering treatments are not adequately effective or well tolerated. The company’s lead program centers on obicetrapib, a low-dose oral CETP inhibitor being studied as a monotherapy and in combination with ezetimibe to help lower LDL cholesterol in cardiovascular settings. NewAmsterdam Pharma also works on broader applications for cardiometabolic care, reflecting its emphasis on non-statin medicine and patient-friendly treatment options. Headquartered in Naarden, the Netherlands, NewAmsterdam Pharma Company N.V. serves the biotechnology and pharmaceuticals market by advancing drug candidates aimed at addressing unmet needs in long-term cardiovascular risk management.

Website

Location

Gooimeer 2-35

Naarden, 1411 DC

Netherlands

Social

What share of all stock conversation is about NAMS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% +0	0% 0

Sep 4

NewAmsterdam Pharma Company N.V.'s ($NAMS) PREVAIL trial is expected to show the efficacy of obicetrapib in reducing cardiovascular events through LDL-C/apoB lowering, a separate and well-established biological pathway.
The recent HORIZON trial result, which showed that a substantial Lp(a) reduction did not significantly reduce cardiovascular events, may weaken the argument that obicetrapib's Lp(a) reduction should be expected to produce a large additional benefit.
The PREVAIL trial is crucial in determining the effectiveness of obicetrapib, and its success despite the HORIZON failure would suggest that lowering LDL/ApoB remains the major driver of its cardiovascular benefit.

Generated by AI

Sentiment

Of the messages about NAMS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100% +25	14.83% -69.47	71.65% +0.3
Bearish	0% 0	0% -25	85.17% +69.47	28.35% -0.3

Dec 10

$NAMS has shown promising results in its cholesterol drug, with a 21% reduction in major cardiovascular events over a year.
Obicetrapib, NewAmsterdam's drug, has the potential to outperform statins in total sales and has no real competition, making it a valuable asset in the market.
The company's stock has surged after positive trial results, with analysts expecting a significant increase in valuation, potentially reaching $5 billion.

Generated by AI

Topics

Of the messages about NAMS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	93.65%	72.56%
Technical Analysis	0%	0%	3.17%	10.86%
Analysts	0%	0%	0%	7.17%
Controversies	0%	0%	1.59%	0.22%
Macro	0%	0%	1.59%	6.05%
Earnings	0%	0%	0%	3.14%

Dec 10

NewAmsterdam Pharma announces positive topline data from pivotal Phase 3 BROADWAY clinical trial evaluating obicetrapib in patients with atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia.
NewAmsterdam Pharma commences $300 million public offering of ordinary shares and pre-funded warrants.
Obicetrapib clinches third positive trial, with shares surging in response to the news.

Generated by AI

Community

Of the messages about NAMS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	19.23%	46.15%	51.42%	44.19%
Newcomers	80.77%	53.85%	48.58%	55.81%

Jun 9

The NewAmsterdam Pharma Company N.V. ($NAMS) has announced positive topline results from its Phase 3 BROADWAY clinical trial for Alzheimer's Disease, showing significant reductions in biomarkers linked to the disease.
The trial's results suggest that the company's cholesterol drug, obicetrapib, may also have a preventive effect on Alzheimer's, with a potential sales range of $15-20 billion if the pills are priced at $3 per piece.
The company's stock has rallied on the positive news, with a 6.11% gap up and a 6.74% intraday gain, and institutional interest is growing, with 168 funds showing a 16.7% increase in holdings.

Generated by AI

NewAmsterdam Pharma

Social

Sep 4

Sentiment

Dec 10

Topics

Dec 10

Community

Jun 9

News

NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease

NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?

Stifel reiterates NewAmsterdam Pharma stock rating on EU approval

European Commission approves obicetrapib for cholesterol treatment

NewAmsterdam Pharma (NAMS) Stock Looks Above Fair Value After Its 139% Run

NewAmsterdam Pharma stock rises as CEO buys $226.5K in stock

Also Discussed

NewAmsterdam Pharma Company N.V.

Company Information

Location

News

NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease

NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?

Stifel reiterates NewAmsterdam Pharma stock rating on EU approval

European Commission approves obicetrapib for cholesterol treatment

NewAmsterdam Pharma (NAMS) Stock Looks Above Fair Value After Its 139% Run

NewAmsterdam Pharma stock rises as CEO buys $226.5K in stock

Also Discussed

Social

Sep 4

Sentiment

Dec 10

Topics

Dec 10

Community

Jun 9